BMS has highlighted results from the P-I/II (KRYSTAL-1) trial arms assessing the safety & effectiveness of Krazati + cetuximab for previously treated KRASG12C mutated locally advanced or metastatic colorectal cancer (CRC) patients at the AACR 2024 and published in Cancer Discovery
The study, with a median follow-up of 11.9mos. among 94 patients, demonstrated ORR of 34%, mPFS of 6.9mos., mOS of 15.9mos., mDoR of 5.8mos. and 85% of patients experienced disease control
In Feb 2024, the US FDA accepted and granted priority review to the company’s sNDA of Krazati + cetuximab for previously treated KRASG12C-mutated locally advanced or metastatic CRC patients with the decision anticipated in Jun 2024
Ref: BMS | Image: BMS
Related Posts:- BMS Reports Results from the P-III (KRYSTAL-12) Study of Krazati for the Treatment of Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
